Selected research
Industry Growth & Trends
Global Topical Drugs CDMO Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Topical Drugs CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Topical Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Topical Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Topical Drugs CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Topical Drugs CDMO market include Piramal Pharma Solutions, Pierre Fabre Group, PCI Pharma Services, MedPharm Ltd., Lubrizol Life Science, DPT Laboratories LTD., Contract Pharmaceuticals Limited, Cambrex Corporation and Bora Pharmaceutical CDMO, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Topical Drugs CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Topical Drugs CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Topical Drugs CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Topical Drugs CDMO.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Topical Drugs CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Topical Drugs CDMO Market by Company
Piramal Pharma Solutions
Pierre Fabre Group
PCI Pharma Services
MedPharm Ltd.
Lubrizol Life Science
DPT Laboratories LTD.
Contract Pharmaceuticals Limited
Cambrex Corporation
Bora Pharmaceutical CDMO
Ascendia Pharmaceuticals
Topical Drugs CDMO Segment by Type
Contract Development
Contract Manufacturing
Topical Drugs CDMO Segment by Application
Semi-Solid Formulations
Solid Formulations
Liquid Formulations
Others
Topical Drugs CDMO Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Topical Drugs CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Topical Drugs CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Topical Drugs CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Topical Drugs CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Contract Development
- Contract Manufacturing
Applications
- Semi-Solid Formulations
- Solid Formulations
- Liquid Formulations
- Others
Companies covered
- Piramal Pharma Solutions
- Pierre Fabre Group
- PCI Pharma Services
- MedPharm Ltd.
- Lubrizol Life Science
- DPT Laboratories LTD.
- Contract Pharmaceuticals Limited
- Cambrex Corporation
- Bora Pharmaceutical CDMO
- Ascendia Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Topical Drugs CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Topical Drugs CDMO Market Size by Region (2021-2032)
- 1.4.1 Global Topical Drugs CDMO Market Size by Region (2021-2026)
- 1.4.2 Global Topical Drugs CDMO Market Size by Region (2027-2032)
- 1.5 Key Regions Topical Drugs CDMO Market Size (2021-2032)
- 1.5.1 North America Topical Drugs CDMO Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Topical Drugs CDMO Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Topical Drugs CDMO Market Size Growth Rate (2021-2032)
- 1.5.4 South America Topical Drugs CDMO Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Topical Drugs CDMO Market Size Growth Rate (2021-2032)
2 Topical Drugs CDMO Market by Type
- 2.1 Type Introduction
- 2.1.1 Contract Development
- 2.1.2 Contract Manufacturing
- 2.2 Global Topical Drugs CDMO Market Size by Type
- 2.2.1 Global Topical Drugs CDMO Market Size Overview by Type (2021-2032)
- 2.2.2 Global Topical Drugs CDMO Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Topical Drugs CDMO Market Size Forecasted by Type (2027-2032)
- 2.3 Global Topical Drugs CDMO Market Size by Regions
- 2.3.1 North America Topical Drugs CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Topical Drugs CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Topical Drugs CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Topical Drugs CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Topical Drugs CDMO Market Size Breakdown by Type (2021-2026)
3 Topical Drugs CDMO Market by Application
- 3.1 Type Introduction
- 3.1.1 Semi-Solid Formulations
- 3.1.2 Solid Formulations
- 3.1.3 Liquid Formulations
- 3.1.4 Others
- 3.2 Global Topical Drugs CDMO Market Size by Application
- 3.2.1 Global Topical Drugs CDMO Market Size Overview by Application (2021-2032)
- 3.2.2 Global Topical Drugs CDMO Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Topical Drugs CDMO Market Size Forecasted by Application (2027-2032)
- 3.3 Global Topical Drugs CDMO Market Size by Regions
- 3.3.1 North America Topical Drugs CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Topical Drugs CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Topical Drugs CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Topical Drugs CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Topical Drugs CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Topical Drugs CDMO Industry Trends
- 4.2 Topical Drugs CDMO Industry Drivers
- 4.3 Topical Drugs CDMO Industry Opportunities and Challenges
- 4.4 Topical Drugs CDMO Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Topical Drugs CDMO Revenue (2021-2026)
- 5.2 Global Topical Drugs CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Topical Drugs CDMO Key Company Headquarters & Area Served
- 5.4 Global Topical Drugs CDMO Company, Product Type & Application
- 5.5 Global Topical Drugs CDMO Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Topical Drugs CDMO Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Topical Drugs CDMO Players Market Share by Revenue in 2025
- 5.6.3 2025 Topical Drugs CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Piramal Pharma Solutions
- 6.1.1 Piramal Pharma Solutions Company Information
- 6.1.2 Piramal Pharma Solutions Business Overview
- 6.1.3 Piramal Pharma Solutions Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Piramal Pharma Solutions Topical Drugs CDMO Product Portfolio
- 6.1.5 Piramal Pharma Solutions Recent Developments
- 6.2 Pierre Fabre Group
- 6.2.1 Pierre Fabre Group Company Information
- 6.2.2 Pierre Fabre Group Business Overview
- 6.2.3 Pierre Fabre Group Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Pierre Fabre Group Topical Drugs CDMO Product Portfolio
- 6.2.5 Pierre Fabre Group Recent Developments
- 6.3 PCI Pharma Services
- 6.3.1 PCI Pharma Services Company Information
- 6.3.2 PCI Pharma Services Business Overview
- 6.3.3 PCI Pharma Services Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 PCI Pharma Services Topical Drugs CDMO Product Portfolio
- 6.3.5 PCI Pharma Services Recent Developments
- 6.4 MedPharm Ltd.
- 6.4.1 MedPharm Ltd. Company Information
- 6.4.2 MedPharm Ltd. Business Overview
- 6.4.3 MedPharm Ltd. Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 MedPharm Ltd. Topical Drugs CDMO Product Portfolio
- 6.4.5 MedPharm Ltd. Recent Developments
- 6.5 Lubrizol Life Science
- 6.5.1 Lubrizol Life Science Company Information
- 6.5.2 Lubrizol Life Science Business Overview
- 6.5.3 Lubrizol Life Science Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Lubrizol Life Science Topical Drugs CDMO Product Portfolio
- 6.5.5 Lubrizol Life Science Recent Developments
- 6.6 DPT Laboratories LTD.
- 6.6.1 DPT Laboratories LTD. Company Information
- 6.6.2 DPT Laboratories LTD. Business Overview
- 6.6.3 DPT Laboratories LTD. Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 DPT Laboratories LTD. Topical Drugs CDMO Product Portfolio
- 6.6.5 DPT Laboratories LTD. Recent Developments
- 6.7 Contract Pharmaceuticals Limited
- 6.7.1 Contract Pharmaceuticals Limited Company Information
- 6.7.2 Contract Pharmaceuticals Limited Business Overview
- 6.7.3 Contract Pharmaceuticals Limited Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Contract Pharmaceuticals Limited Topical Drugs CDMO Product Portfolio
- 6.7.5 Contract Pharmaceuticals Limited Recent Developments
- 6.8 Cambrex Corporation
- 6.8.1 Cambrex Corporation Company Information
- 6.8.2 Cambrex Corporation Business Overview
- 6.8.3 Cambrex Corporation Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Cambrex Corporation Topical Drugs CDMO Product Portfolio
- 6.8.5 Cambrex Corporation Recent Developments
- 6.9 Bora Pharmaceutical CDMO
- 6.9.1 Bora Pharmaceutical CDMO Company Information
- 6.9.2 Bora Pharmaceutical CDMO Business Overview
- 6.9.3 Bora Pharmaceutical CDMO Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Bora Pharmaceutical CDMO Topical Drugs CDMO Product Portfolio
- 6.9.5 Bora Pharmaceutical CDMO Recent Developments
- 6.10 Ascendia Pharmaceuticals
- 6.10.1 Ascendia Pharmaceuticals Company Information
- 6.10.2 Ascendia Pharmaceuticals Business Overview
- 6.10.3 Ascendia Pharmaceuticals Topical Drugs CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Ascendia Pharmaceuticals Topical Drugs CDMO Product Portfolio
- 6.10.5 Ascendia Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Topical Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Topical Drugs CDMO Market Size by Country (2021-2026)
- 7.3 North America Topical Drugs CDMO Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Topical Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Topical Drugs CDMO Market Size by Country (2021-2026)
- 8.3 Europe Topical Drugs CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Topical Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Topical Drugs CDMO Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Topical Drugs CDMO Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Topical Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Topical Drugs CDMO Market Size by Country (2021-2026)
- 10.3 South America Topical Drugs CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Topical Drugs CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Topical Drugs CDMO Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Topical Drugs CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst